Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis
William J. Sandborn(University of San Diego), Paul Rutgeerts(KU Leuven), Walter Reinisch(Medical University of Vienna), Peter R. Gibson(Monash University), Jean‐Frédéric Colombel(Mount Sinai Hospital), Brian G. Feagan(Western University), Gunnar Järnerot(Örebro University Hospital), Colleen Marano(Johnson & Johnson (United States)), Cynthia Guzzo(Janssen (Belgium)), Judith Collins(Oregon Health & Science University), Jewel Johanns(Johnson & Johnson (United States)), Richard Strauß(Hennepin County Medical Center), Hongyan Zhang(Northwest A&F University), Omoniyi J. Adedokun(Western University)
Cited by 725
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k